The GPCR structures in an inactive conformation solved recently^[@R3]-[@R12]^ largely advance our understanding of the molecular signalling mechanisms of the receptors. The first details of GPCR activation were provided by the structure of bovine opsin in an active conformation complexed with a G-protein C-terminal peptide (GαCT)^[@R1]^. Most recently, Kobilka and colleagues obtained the crystal structures of β~2~AR in an active state with a camelid antibody fragment (nanobody, Nb80)^[@R2]^ and with a heterotrimeric Gs-protein^[@R13]^. In these structures, the complementarity-determining region (CDR-3) of Nb80 and C-terminal α-helix of a subunit (Gαs) of Gs-protein were located in the same pocket as for GαCT in the opsin structure. They showed that Nb80 and Gs protein change the conformational equilibrium of β~2~AR toward the active state in a similar manner, thereby substantially increase their agonist affinities^[@R2],[@R13]^.

A~2A~AR is responsible for regulating blood flow to the cardiac muscle and is important in the regulation of glutamate and dopamine release in the brain^[@R14]^. Caffeine is a well-known antagonist of this receptor. Strong epidemiological evidence indicates that coffee drinkers have a lower risk of Parkinson's disease^[@R15]^. The structure of A~2A~AR has been reported^[@R9],[@R16]^ as a complex with both an antagonist (ZM241385) and an agonist (UK-432097). These structures reveal the molecular framework of the receptor; however, in both cases the intracellular loop 3 (ICL3), critical for G-protein binding, has been replaced by T4-lysozyme (T4L).

Here, we report the crystal structure of A~2A~AR with complete ICL3 in complex with a mouse monoclonal-antibody Fab-fragment, Fab2838. A~2A~AR was expressed in *Pichia pastoris* and the antibody was raised to the purified receptor with antagonist (ZM241385) bound using the conventional mouse-hybridoma system combined with improved immunisation and screening methods (for details, see [Methods](#APP1){ref-type="app"}). Fab2838, a Fab fragment generated from one (IgG2838) of the obtained antibodies completely inhibited binding of the agonist \[^3^H\]-NECA but did not affect binding of the antagonist \[^3^H\]-ZM241385 ([Fig. 1a,d](#F1){ref-type="fig"} and [Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}). The results were confirmed by competition binding assays (for details, see [Supplementary Discussion](#SD2){ref-type="supplementary-material"} and [Fig. 1](#SD2){ref-type="supplementary-material"}). These findings suggest that Fab2838 induces an inactive conformation, (*i.e.* to which agonist cannot bind) of the A~2A~AR ligand-binding pocket without blocking the ligand-binding site.

We crystallised A~2A~AR with Fab2838 in the presence of ZM241385 and solved the structure at a resolution of 2.7 Å ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Since the occupancy of ZM241385 in the structure was low for unknown reasons, we repeated the experiments and obtained a higher occupancy structure at 3.1 Å ([Supplementary Table 2](#SD2){ref-type="supplementary-material"} and [Supplementary Fig. 3 and 4](#SD2){ref-type="supplementary-material"}). Except for the occupancy of the ligand, the two structures are almost identical (RMSD of Cα; 0.57 Å) ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). ZM241385 occupies the ligand-binding pocket on the extracellular side by making hydrophobic interactions with F168^5.29^ and I274^7.39^, and hydrogen-bonds with N253^6.55^ as observed in the A~2A~AR-T4L structure ([Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}). While the overall structure of A~2A~AR in the A~2A~AR-Fab2838 complex is similar to that of the T4L construct (PDB; 3EML) (RMSD of Cα; 0.85 Å), there is a major difference around the intracellular portions of helices V and VI, which are connected by ICL3, where T4L is inserted in A~2A~AR-T4L ([Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). In our structure, ICL3 forms two regular helices, effectively continuations of helices V and VI respectively, connected by a short turn ([Supplementary Fig. 6a](#SD2){ref-type="supplementary-material"}).

The A~2A~AR--Fab2838 structure has a modified 'ionic lock' where E228^6.30^ (helix VI) and R102^3.50^ of the D(E)RY motif (helix III) interact *via* a water molecule (W1; [Fig. 2c,d](#F2){ref-type="fig"}). In the inactive bovine rhodopsin structure, the equivalent residues form a direct salt-bridge^[@R3]^ ([Supplementary Fig. 7](#SD2){ref-type="supplementary-material"}). R102^3.50^ of A~2A~AR-Fab2838 forms salt-bridges/hydrogen-bonds with D101^3.49^, Y112 in ICL2 and T41^2.39^ as observed in the A~2A~AR-T4L structure ([Supplementary Fig. 5b](#SD2){ref-type="supplementary-material"}). Because of the insertion of the water molecule, E228^6.30^ shifts towards the cytoplasmic space, as compared to the equivalent residue in rhodopsin (E247^6.30^), resulting in the formation of a salt bridge with R220 in the short helical turn of ICL3. This interaction may be important in the formation of the helical structure in ICL3. The 'ionic lock' has not been observed in the crystal structures of other inactive GPCRs^[@R6]-[@R11]^, including A~2A~AR-T4L, except for the D3 dopamine receptor^[@R12]^. This may be because the ICL3s in the other structures were modified to stabilise the protein. While this manuscript was in review, the crystal structures of thermostabilised A~2A~AR mutants with native ICL3 were published^[@R17],[@R18]^. The antagonist-bound inactive structures have the 'ionic lock'^[@R18]^. Thus, the 'ionic lock' of A~2A~AR seems to stabilise the inactive conformation of the protein, which is why the receptor has a low basal activity.

Fab2838 binds on the intracellular side of the receptor ([Fig. 2a](#F2){ref-type="fig"}). CDR-H3 of Fab2838 is unusually long and penetrates into a pocket formed by helices II, III, VI and VII ([Fig. 2b](#F2){ref-type="fig"}). CDR-H3 interacts with the surrounding helices by forming 6 hydrogen bonds and 8 van der Waals contacts ([Fig. 2c,d](#F2){ref-type="fig"}). The most extensive interactions are with helix II (mainly through hydrogen bonds) and helix VI (mainly through van der Waals contacts). In addition, a hydrogen-bond network including 2 water molecules is observed between CDR-H3 and helices III and VI ([Fig. 2c,d](#F2){ref-type="fig"}). This hydrogen-bond network together with the van der Waals interactions seem to stabilise the modified 'ionic lock' interaction between E228^6.30^ (helix VI) and R102^3.50^ (helix III) discussed above. Other CDRs further stabilise the A~2A~AR--Fab2838 complex by forming 14 hydrogen bonds with helices VI and VIII and ICLs 1, 2, and 3 ([Fig. 2b](#F2){ref-type="fig"}). The extensive interactions explain the high affinity of Fab2838 (*K*~D~ = 4.4 nM) ([Supplementary Fig. 8](#SD2){ref-type="supplementary-material"}).

The Fab2838 CDR-H3 binding site in A~2A~AR is similar to those for Nb80 CDR-3 in β~2~AR^[@R2]^ and for GαCT in opsin^[@R1]^. A critical difference is that Fab2838 stabilises an inactive conformation whereas the others recognise active conformations of the receptors. These structures are compared in [Figure 3](#F3){ref-type="fig"}. In the opsin structure, GαCT, which forms a short α-helix, fits into a large pocket formed by helices II, III, V, VI, and VII interacting with the Arg residue of the D(E)RY motif in helix III ([Fig. 3](#F3){ref-type="fig"}, left panels). CDR-3 of Nb80 in the β~2~AR structure binds in a similar position to GαCT although CDR-3 forms a β-hairpin^[@R1]^ ([Fig. 3](#F3){ref-type="fig"}, middle panels). Interestingly, CDR-H3 of Fab2838 also forms a β-hairpin but induces a differently shaped binding-pocket ([Fig. 3c](#F3){ref-type="fig"}). In the β~2~AR structure, CDR-3 of Nb80 is positioned between helices III and VI, whereas in the A~2A~AR structure CDR-H3 of Fab2838 is \~ 6 Å closer to helices II and VII ([Fig. 3b](#F3){ref-type="fig"} and [Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). This allows the close association of helices III and VI and the formation of the modified 'ionic lock' between R102^3.50^ in helix III and E228^6.30^ in helix VI, consequently stabilising the inactive conformation. In the β~2~AR-Gs protein complex structure, the C-terminal α-helix (α5) of Gαs also binds in a similar position to CDR-H3^[@R13]^ ([supplementary Fig. 10](#SD2){ref-type="supplementary-material"}). The conformational changes of α5 together with the Gαs N-terminal region induced by the activated receptor was proposed to lead a nucleotide exchange from GDP to GTP in Gαs and to subsequent dissociation of the subunit from the receptor^[@R19]^. Thus, the binding pocket formed by helices II, III, VI, and VII seems to be the key site for the signal transfer between GPCR and G-protein.

A possible inactivation mechanism of A~2A~AR by Fab2838 is summarised as follows. Agonist binding induces large displacements of the intracellular ends of helices III, VI, and VII^[@R16],[@R17]^, which are essential to form the G-protein binding-pocket^[@R13],[@R19]^ ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). This indicates that the signal from the ligand-binding pocket is transferred through these helices and the conformations of the two pockets are strongly coupled. Our agonist and antagonist binding experiments indicate that this coupling also allows signal transfer in a reverse direction, from the G-protein binding to the ligand-binding pockets ([Fig. 1](#F1){ref-type="fig"}). CDR-H3 of Fab2838 locks the positions of helices III, VI, and VII from the cytoplasmic side, leading to an inactive conformation of the extracellular ligand-binding pocket to which agonists cannot bind probably because of the rearrangement of the side chains at the bottom of the ligand-binding pocket including W246^6.48^, the toggle switch for activation (for details, see [Supplementary Fig. 1 and 11](#SD2){ref-type="supplementary-material"}). A similar conceptual model on the β~2~AR activation was reported by Kobilka, Sunahara, and colleagues^[@R20]^. In the case of β adrenergic receptors, the conformational coupling of the ligand and G-protein binding pockets seems less strict as demonstrated in the structures of β~1~AR-agonist complexes^[@R21]^ and β~2~AR-irreversible agonist complex^[@R22]^. This may be because the A~2A~AR and β~1~/β~2~AR agonists interact with different helices in the binding pockets (for details, see [Supplementary Discussion](#SD1){ref-type="supplementary-material"}).

Antibody fragments (and nanobodies) such as Nb80 and Fab2838 that recognise conformational epitopes of GPCRs have great potential for GPCR studies *in vitro* and *in vivo.* Although antibodies recognising the intracellular surface are not suitable for direct therapeutic use, the CDR structures should provide useful information to design peptides or small-molecule compounds against their clearly defined pockets to control the activation states of GPCRs. The antibody-fragments will be also useful tools to study ligand-binding kinetics of GPCRs because they can separate ligand-binding from equilibrium-shifts between different activation states of the receptors. Our approach based on the conventional mouse-hybridoma system allows us to raise antibodies against various receptors in 3-4 months using standard laboratory equipment.

METHODS SUMMARY {#S1}
===============

Expression and purification {#S2}
---------------------------

A~2A~AR ^N154Q^ (residues 1-316) was expressed in *P. pastoris* as described previously^[@R23]^ and purified as described in [Methods](#APP1){ref-type="app"}.

Antibody generation {#S3}
-------------------

MRL/lpr mice were immunised with the purified A~2A~AR with the antagonist ZM241385. Antibodies were raised to recognise conformational epitopes of A~2A~AR using the conventional mouse-hybridoma system^[@R24]^ combined with new screening methods as described in [Methods](#APP1){ref-type="app"}. The Fab fragments were obtained by papain cleavage and purified by anion-exchange column chromatography.

Crystallisation, data collection, and structure determination {#S4}
-------------------------------------------------------------

Purified A~2A~AR was mixed with the Fab fragment and the A~2A~AR -Fab complex was purified twice by gel filtration chromatography. Crystals were grown by vapour diffusion under the conditions described in the [Methods](#APP1){ref-type="app"}. Diffraction data were collected from a single cryo-cooled crystal on beamline I24 at the Diamond Light Source Ltd., UK. The structures were solved by molecular replacement using the receptor from the A~2A~AR-T4L structure (PDB code, 3EML) and an antibody Fab-fragment structure (PDB code 1P7K) as search models. Data collection and refinement statistics are summarised in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}.
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METHODS {#S6}
=======

Construction of A~2A~AR expression vectors for *Pichia pastoris* {#S7}
----------------------------------------------------------------

The coding sequence of A~2A~AR from residues 1 to 316 including the N-terminal ![](ukmss-40157-ig0004.jpg) factor, FLAG-tag sequence, and C-terminal His (10)-tag was synthesised by optimisation of codon usage for *P. pastoris* (TAKARA bio Inc.). In the construct, N154 was also replaced by Gln to eliminate N-linked glycosylation. The DNA fragment was inserted into the multiple cloning site of the pPIC9K vector, and the linearised vector was transformed into the *P. pastoris* strain SMD1163 (Invitrogen) as described previously^[@R23]^. The transformed cells were stored as glycerol stocks at −80°C.

Expression and purification of A~2A~AR {#S8}
--------------------------------------

A~2A~AR was expressed in *P. pastoris* as described previously^[@R23]^. Cells were suspended in buffer A (50 mM Sodium Phosphate, 100 mM NaCl, 5% glycerol, 2 mM EDTA, protease inhibitor cocktail (Roche); pH 7.4) and disrupted with glass beads (0.5 mm Biospec) by vigorous agitation at 350 rpm for 2 h at 4°C. Following removal of unbroken cells and cell debris at 10,000 × *g*, membranes were isolated by ultracentrifugation at 100,000 × *g* for 45 min. Membranes were resuspended in buffer B (20 mM Hepes, 500 mM NaCl, 30 % glycerol, EDTA-free protease inhibitor cocktail (Roche); pH 7.0) and solubilised by 1% n-dodecyl β-D-maltoside (DDM; Anatrace) containing 0.2% cholesterol hemi succinate (CHS; Sigma) in the presence of 4 mM theophylline (antagonist) for 1-2 h at 4°C. After ultracentrifugation, the supernatant was supplemented with solid imidazole to a final concentration of 40 mM and incubated overnight with a TALON immobilised metal ion affinity chromatography resin (Clonetech) at 4°C with gentle rotation (1 mL of TALON resin/150 mg of total protein). The resin was washed with buffer C (20 mM Hepes, 250 mM NaCl, 10% glycerol, protease inhibitor cocktail, 0.05% DDM, 0.01% CHS; pH 7.0) containing 20 mM imidazole, and the bound A~2A~AR was eluted with buffer C containing 300 mM imidazole. The purified sample was incubated overnight with ConA resin at 4°C to remove contaminating glycosylated proteins and was collected in the flow-through fraction. The final purified sample was dialysed against buffer C and concentrated to approximately 20 mg/mL by ultrafiltration (ULTRA-4 100 K, Millipore).

Construction, expression, and purification of A~2A~AR-T4L {#S9}
---------------------------------------------------------

A~2A~AR-T4L is a variant of A~2A~AR in which the ICL3 region is replaced with a bacteriophage T4 lysozyme (T4L): N2 to Y161 of T4L were inserted between L208 and R222 within the ICL3 region replacing residues K209 to A221. A~2A~AR-T4L was expressed in *P. pastoris* and purified as described above.

Antibody generation {#S10}
-------------------

All animal experiments described in this study conformed to the guidelines outlined in the Guide for the Care and Use of Laboratory Animals of Japan and were approved by the University of Tokyo Animal Care Committee (approval no. RAC07101). To raise antibodies against conformational epitopes of A~2A~AR, we modified existing protocols for immunisation and screening of mouse monoclonal antibodies. A detailed description of these modified protocols will be published elsewhere. Briefly, MRL/lpr mice were immunised with 0.1 mg purified A~2A~AR-antagonist ZM241385 complex 3 times with 2 week intervals. The immunised mice were sacrificed and single cell suspensions were prepared from the spleen. These cells were fused with NS-1 myeloma cells using polyethylene glycol (PEG) according to conventional methods^[@R24]^. Primary screening of hybridoma culture supernatants was performed using the liposome ELISA assay. To screen antibodies that specifically recognise native receptors, we developed a novel ELISA method using proteoliposomes. For 'liposome-ELISA', we used purified A~2A~AR reconstituted into liposomes containing biotinyl phosphatidylethanolamine (Avanti) to maintain the protein in its native conformation and effectively immobilise liposomes onto streptavidin-coated plates (Nunc). To eliminate antibodies recognising flexible loops, N (and C)-termini or unstructured regions of A~2A~AR, we performed ELISA using A~2A~AR denatured with 1% sodium dodecyl sulphate. Denatured ELISA-negative cells were collected and evaluated using a BIAcore T100 (GE Healthcare) as described below. The selected cells were isolated by limiting dilution to establish monoclonal hybridoma cell lines producing antibodies against A~2A~AR. For large-scale antibody production, the monoclonal hybridoma cells were inoculated into BALB/c athymic nude mice. IgG was collected from mouse ascites fluid by precipitating twice with 50% ammonium sulphate and purified using Melon Gel (Thermo) according to the manufacturer's protocol. Fab fragments were obtained by proteolytic cleavage of IgG with papain (Worthington) and purified by anion-exchange column chromatography (DEAE 5-PW, TOSOH). The sequences of Fab fragments were determined according to the standard 5′-RACE method using total RNA isolated from hybridoma cells.

Binding assay by surface plasmon resonance {#S11}
------------------------------------------

The BIAcore T100 system and reagents, including sensor chips and amine coupling kit, were obtained from GE Healthcare. Monoclonal anti-mouse Fc antibody (200 μg/mL; Millipore) was immobilised on a CM5 sensor chip using the amine coupling kit according to the manufacturer's instructions. Antibodies in hybridoma culture supernatants (50 μL) or purified monoclonal antibodies (50 μg/mL) were tightly trapped by the Fc-antibody fixed on the sensor chip. The antibodies bound tightly so as not to be released from the surface when washing with buffer D (20 mM Hepes, 100 mM NaCl, 0.05% DDM, 0.01% CHS; pH 7.0). Purified A~2A~AR (or A~2A~AR-T4L) was passed over the surface and the specific binding was monitored for 2 min at 20°C. Subsequently, the sensor surface was washed with buffer D and the dissociation was monitored for 6 min at 20°C. Association and dissociation rate constants (*k*~on~ and *k*~off~) were determined using a curve-fitting protocol as implemented in the BIAevaluation software (Version 1.1, GE Healthcare) based on the Langmuir isotherm model assuming 1:1 binding stoichiometry.

Ligand binding assays {#S12}
---------------------

Ligand binding assays were performed using radioligands of the antagonist \[^3^H\]-ZM241385 and the agonist \[^3^H\]-NECA (GE Healthcare). For single-point binding assays, 5 nM \[^3^H\]-ZM241385 or 5 μM \[^3^H\]-NECA was incubated in 50 μL of buffer D containing 5 nM or 50 nM purified A~2A~AR with or without 500 nM antibody for 1 h on ice. For saturation-binding assays, varying concentrations of \[^3^H\]-ZM241385 or \[^3^H\]-NECA were incubated in 50 μL of buffer D containing 5 nM or 50 nM purified A~2A~AR with or without 500 nM antibody (Fab2838) for 1 h on ice. Receptor-bound ligands were separated by gel filtration^[@R25]^ and radioactivity was measured using a LS6500 scintillation counter (Beckman). Data were analysed by a nonlinear-regression-fitting program using the GraphPad Prism software. Competition assays with antagonists (SCH442416, theophylline) and agonists (NECA, adenosine) were performed in the presence of 1.0 nM \[^3^H\]-ZM241385 for A~2A~AR or 1.5 nM for A~2A~AR-Fab (corresponding to the respective *K*~D~s).

Purification and crystallisation of the A~2A~AR-Fab complex {#S13}
-----------------------------------------------------------

Purified A~2A~AR and the Fab fragments were mixed at 1:1.2 molar ratio and were incubated on ice for 1 h. The mixture was loaded onto a Superdex 10/300 column (GE Healthcare) equilibrated with buffer C and eluted using the same buffer. The gel filtration step was repeated twice to ensure successful crystallisation of the A~2A~AR-Fab complex. Fractions containing the complex were concentrated to approximately 20 mg/mL by ultrafiltration (ULTRA-4 100 K, Millipore). Initial crystals were obtained using MemGold (Molecular Dimensions Ltd.). After optimisation, well-diffracting crystals were obtained in hanging drops by vapour diffusion at 20°C with the protein solution containing 0.3-0.6% octyl-thioglucoside and the reservoir solution (1 μL) containing 30% PEG400, 0.1 M MES (pH 6.5) and 0.2 M MgCl~2~. Crystals appeared after 1 day and grew to maximum dimensions in 1 week before being flash-frozen and stored in liquid nitrogen.

Data collection and structure determination {#S14}
-------------------------------------------

Diffraction data were collected from single cryo-cooled crystals (100K) on beamline I24 at Diamond Light Source Ltd., UK using a 10-μm focused beam (wavelength 0.9795 Å) and a pilatus 6 M detector (Dectris Ltd., Switzerland). Data were processed using MOSFLM and SCALA from the CCP4 program suite^[@R26]^. The structure was initially solved using the 2.7 Å data. Molecular replacement was carried out with PHASER^[@R27]^ using the receptor from the A~2A~AR-T4 lysozyme fusion structure (PDB code 3EML) and an antibody fragment (PDB code 1P7K) as search models. Iterative cycles of model building and structure refinement were performed using Coot^[@R28]^, Refmac5^[@R29]^ and phenix.refine in the PHENIX program package^[@R30]^. The final model from this refinement was used as the initial model for refinement against the 3.1 Å data. The refinement was carried out similarly to above. Model validation was performed using Procheck^[@R31]^ and MolProbity^[@R32]^. The resulting crystallographic and refinement statistics are summarised in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}. Disordered region of A~2A~AR was predicted by the RONN program^[@R33]^. Figures were prepared using PyMOL (The PyMOL Molecular Graphics System, Version 1.3, Schrodinger, LLC.).

![Effect of Fab2838 on A~2A~AR -ligand binding\
**a,** Saturation binding curves for an antagonist \[^3^H\]-ZM241385 binding to A~2A~AR with (open circle) or without (closed circle) Fab2838. **b** and **c**, Inhibition of \[^3^H\]-ZM241385 binding by the antagonists, theophylline (**b**) and SCH442416 (**c**) with (open circles) and without (closed circles) Fab2838. The binding of \[^3^H\]-ZM241385 in the absence of competitor was set at 100%. **d,** Similar to **a**, but for the agonist \[^3^H\]-NECA. **e** and **f**, Similar to **c** and **d** but for the agonists, adenosine (**e**) and NECA (**f**), respectively. All data are the mean ± standard estimated errors (SEM) of three independent experiments performed in duplicate.](ukmss-40157-f0001){#F1}

![Structure of the A~2A~AR complex with an antibody Fab2838 fragment\
**a**, Overall structure viewed parallel to the membrane. A~2A~AR and the Fab light and heavy chains are shown in blue-grey, cyan, and magenta, respectively. The three disulfide bonds in the ECLs are represented by yellow sticks. The bound antagonist ZM241385 in the ligand-binding pocket is shown as a space-filling model. The complementarity-determining regions (CDRs) of Fab2838 are as follows: CDR-H1, yellow; CDR-H2, orange; CDR-H3, red; CDR-L1, green; CDR-L2, purple; CDR-L3, marine. **b**, Surface representation of the interface between A~2A~AR (top) and Fab2838 (bottom). Compared to **a**, A~2A~AR has been rotated 90° around a horizontal axis, whereas Fab2838 is shown in the same orientation. **c**, View of the A~2A~AR (green residues) and CDR-H3 (orange residues) interface. Red dotted lines indicate polar interactions. **d**, Schematic representation of the A~2A~AR and CDR-H3 interface.](ukmss-40157-f0002){#F2}

![Comparison of the structures of opsin-GαCT, β2AR-Nb80 and A~2A~AR-Fab2838 complexes\
Left, middle and right panels show the structures of an active form of opsin with GαCT (opsin in green and GαCT in yellow), an active form of β~2~AR with Nb80 CDR-3 (β~2~AR in brown and Nb80 CDR-3 in blue) and an inactive form of A~2A~AR with Fab2838 CDR-H3 (A~2A~AR in blue-grey and Fab2838 CDR-H3 in red). **a**, Views parallel to the membrane. Bound ligands are shown as stick models in β~2~AR and A~2A~AR. The residues involved in the 'ionic lock' formation are also shown. Nitrogen and oxygen atoms are in blue and red, respectively. **b**, Cytoplasmic views of the complexes. **c**, Surface representations of cytoplasmic surfaces of the receptors. Surfaces within 4 Å of GαCT/CDR-3/CDR-H3 are red.](ukmss-40157-f0003){#F3}
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